RECURRENT OVARIAN CARCINOMA

This study compares two chemotherapy regimens (carboplatin+paclitaxel vs oxaliplatin+capecitabine), with or without the drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 participants with newly diagnosed or recurrent disease are enrolled…

This study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…

This early-phase study tests a new drug (berzosertib) added to standard chemotherapy for women with ovarian, peritoneal, or fallopian tube cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination works better than chemo alon…

This early-stage trial tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard therapy. Patients receive their own T cells that have been genetically modified to recognize and attack cancer cells, along with a drug ca…

This study tests a drug called adavosertib, given alone or with olaparib, in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitor treatment. The goal is to see if these drugs can shrink tumors or slow their growth. Ab…

This early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…

This early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…

This study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …

This study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…

This study tests a drug called tazemetostat in people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if it can shrink tumors or slow the disease. About 62 participant…

This study tests whether adding an experimental drug called M6620 to standard chemotherapy (gemcitabine) works better than gemcitabine alone for people with ovarian, peritoneal, or fallopian tube cancer that has returned and no longer responds to platinum-based treatments. About …

This study compares three different combinations of chemotherapy and targeted drugs in 444 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemotherapy. The goal is to find which combination best delays cancer growt…

This phase 3 study tested whether the targeted drugs olaparib (alone or combined with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that came back after initial treatment. About 579 women with…

This study tests a combination of two drugs—veliparib and topotecan—in people with advanced solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. About 88 adults are taking part in t…

This study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…

This study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can delay cancer progression in people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. Participants have a rising CA-125 blood marker but no visi…

This early-phase study tests whether giving a dose of heated chemotherapy directly into the abdomen during surgery can help lower the risk of cancer returning in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants with stage III or I…

This study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…

This study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…

This early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a program called HOPE designed to reduce feelings of hopelessness and helplessness in women whose ovarian cancer has returned. About 60 participants will either receive the HOPE workshops or standard care. The goal is to see if the program is feasible and improve…

This study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…